Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

The University of Alabama at Birmingham

Status and phase: Withdrawn; Phase 1

Conditions: Lymphoma; Leukemia

Treatments: Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

Study type: Interventional

Funder types: Other

Identifiers

NCT00002956

UAB-9739

CDR0000065433

NCI-V97-1176

IUMC-9611-37

Details and patient eligibility

About

RATIONALE: Donor lymphocytes that have been exposed to Epstein-Barr virus may be able to help the body kill cancers associated with this virus.

PURPOSE: Phase I trial to study the effectiveness of Epstein-Barr virus-specific T cells derived from matched donors in organ transplant patients with lymphoproliferative diseases associated with Epstein-Barr virus.

Full description

OBJECTIVES: I. Examine the toxic effects of allogeneic Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes (CTL) for the treatment of EBV lymphoproliferative diseases (LPD) in organ transplant recipients. II. Determine the level of in vivo expansion of allogeneic CTL and the period of time during which these CTL's can be detected in the blood of recipients of the T cell infusions.

OUTLINE: Donors undergo leukapheresis, and Epstein-Barr virus (EBV) specific cytoxic T lymphocytes are cultivated in vitro. Patients receive infusions of EBV specific cytotoxic T lymphocytes over 5 to 10 minutes on weeks 0, 2, and 4. Patients with stable disease and those achieving partial remission are followed weekly for signs of disease progression.

PROJECTED ACCRUAL: 10 patients will be accrued in this study.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria:

• Radiographic evidence of lymphadenopathy or lymphomatous lesions combined with clinical signs of Epstein-Barr virus lymphoproliferative disease (EBV LPD), such as fevers and lymphadenopathy
• following an organ transplant Persistent, progressive, or unresponsive disease despite decreased immunosuppression, chemotherapy, or radiation therapy EBV LPD must be of host origin
• At least 4 weeks
• Patients serologically hepatitis B and C positive may receive cytotoxic
• T- lymphocytes (CTL) from donors who are serologically positive for the same virus
• Must have an HLA identical or HLA haploidentical donor

Exclusion

• hepatic dysfunction SGOT/SGPT less than 2.5 times upper limit of normal (unless liver metastases present)
• Bilirubin less than 2.0 mg/dL
• renal dysfunction
• Creatinine clearance at greater than 50 mL/min
• cardiac dysfunction
• neurologic dysfunction
• pulmonary dysfunction
• patients developing EBV LPD who have a donor origin lymphoma
• HIV-1 positive
• Not capable of undergoing leukapheresis

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

infusions of EBV specific cytotoxic T lymphocytes

Experimental group

Description:

Donors undergo leukapheresis, and Epstein-Barr virus (EBV) specific cytoxic T lymphocytes are cultivated in vitro. Patients receive infusions of EBV specific cytotoxic T lymphocytes over 5 to 10 minutes on weeks 0, 2, and 4. Patients with stable disease and those achieving partial remission are followed weekly for signs of disease progression

Treatment:

Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes